The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension-Reference-Cited by-同舟云学术

The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension

Published:2020-03 Issue:1 Volume:524 Page:50-56
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Chowdhury Biswajit,Luu Albert Z.,Luu Vincent Z.,Kabir M. Golam,Pan Yi,Teoh Hwee,Quan Adrian,Sabongui Sandra,Al-Omran Mohammed,Bhatt Deepak L.,Mazer C. David,Connelly Kim A.,Verma Subodh,Hess David A.

Funder

Canadian Institutes of Health Research

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference41 articles.

1. Medical therapy for heart failure associated with pulmonary hypertension;Zelt;Circ. Res.,2019

2. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients;Sikirica;BMC Health Serv. Res.,2014

3. Update on pulmonary arterial hypertension research: proceedings from a meeting of experts;McLaughlin;Curr. Med. Res. Opin.,2018

4. Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States;Kirson;Curr. Med. Res. Opin.,2011

5. Pulmonary arterial hypertension;Badesch;Chest,2010

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies;Chemico-Biological Interactions;2024-11

2. Dapagliflozin alleviates right heart failure by promoting collagen degradation by reducing ROS levels;European Journal of Pharmacology;2024-10

3. Empagliflozin inhibits PASMCs Phenotypic transition via downexpressing SYK and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension;2024-08-21

4. Empagliflozin Attenuates Pulmonary Arterial Remodeling Through Peroxisome Proliferator-Activated Receptor Gamma Activation;ACS Pharmacology & Translational Science;2024-08-01

5. Unlocking the Potential: Angiotensin Receptor Neprilysin and Sodium Glucose Co-Transporter 2 Inhibitors for Right Ventricle Dysfunction in Heart Failure;Medicina;2024-07-09